2023-03-28 16:04:22 ET
- Danimer Scientific press release ( NYSE: DNMR ): FY GAAP EPS of -$1.78 in-line.
- Revenue of $53.2M (-9.4% Y/Y) in-line.
- Gross profit for 2022 was $(10.4) million compared to $0.9 million for the prior period. Adjusted gross profit was $4.4 million in 2022 compared to $11.0 million in 2021,
- Full-year 2022 net loss was $(179.8) million, which included a charge of $(62.7) million for goodwill impairment in the third quarter.
- Full-year 2022 Adjusted EBITDA was $(45.0) million, consistent with the guidance range the Company first provided in May of 2022 and its most recent guidance of $(45.0) million to $(40.0) million.
- Cash and cash equivalents at year-end was $62.8 million, consistent with the Company’s most recent guidance of $60 million to $65 million.
- Full-year capital expenditures were $164.5 million, consistent with the Company’s most recent guidance of $165 million to $170 million.
-
For the full year 2023, the Company today provided the following guidance:
-
Full-year Adjusted EBITDA is expected to be in the range of $(23) million to $(31) million.
For further details see:
Danimer Scientific GAAP EPS of -$1.78 in-line, revenue of $53.2M in-line